The Sensory Organ Drugs market in G20 has been experiencing growth in recent years.
Customer preferences: Customers in the Sensory Organ Drugs market are increasingly seeking treatments for conditions related to aging populations, such as age-related macular degeneration and cataracts. Additionally, there is a growing demand for treatments for conditions related to digital eye strain, as more people spend extended periods of time in front of screens.
Trends in the market: In the United States, the Sensory Organ Drugs market is expected to grow due to an aging population and increasing prevalence of conditions such as glaucoma. In Japan, the market is also expected to grow due to an aging population, but with a focus on treatments for dry eye syndrome. In China, the market is expected to see significant growth due to an increasing prevalence of myopia, particularly among younger populations. In Europe, the market is expected to see growth due to the increasing availability of innovative treatments and the rise of telemedicine.
Local special circumstances: In Japan, there is a strong focus on preventative measures for eye health, leading to a high demand for eye drops and vitamins. In China, there is a cultural emphasis on education and academic success, leading to a high prevalence of myopia among younger populations. In the United States, there is a growing trend towards self-care and natural remedies, leading to an interest in alternative treatments for eye conditions.
Underlying macroeconomic factors: The aging populations in many G20 countries are driving demand for Sensory Organ Drugs, as age-related conditions become more prevalent. Additionally, the increasing prevalence of digital eye strain is a factor in the growth of the market. The rise of telemedicine is also contributing to the growth of the market, as patients are able to access care more easily and conveniently. Finally, the increasing availability of innovative treatments is driving demand for Sensory Organ Drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
